We are live on ! Find out more
FCMI

Foresite Capital Management III Portfolio holdings

AUM $37.9M
1-Year Est. Return 6.87%
This Fund
S&P 500
This Quarter Est. Return
-7.35%
1 Year Est. Return
-6.87%
3 Year Est. Return
+444.07%
5 Year Est. Return
+547.28%
10 Year Est. Return
–
AUM
$39.5M
AUM Growth
-$32.6M
Cap. Flow
-$30.7M
Cap. Flow %
-77.73%
Top 10 Hldgs %
100%
Holding
8
New
2
Increased
–
Reduced
–
Closed
4

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$19.9M
2
NTRA icon
Natera
NTRA
+$9.44M

Top Sells

Rank Stock Value
1
ACRS icon
Aclaris Therapeutics
ACRS
+$35.2M
2
XLRN
Acceleron Pharma
XLRN
+$18.7M
3
EPZM
Epizyme, Inc
EPZM
+$5.11M
4
NVAX icon
Novavax
NVAX
+$1.04M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
1
Ascendis Pharma A/S
ASND
$16.3B
$18M 45.53%
+133,691
New +$19.9M
NTRA icon
2
Natera
NTRA
$36.7B
$8.5M 21.51%
+91,000
New +$9.44M
VRNA
3
DELISTED
Verona Pharma
VRNA
$7.47M 18.9%
1,111,112
– –
CBAY
4
DELISTED
Cymabay Therapeutics
CBAY
$5.55M 14.05%
1,641,804
– –
ACRS icon
5
Aclaris Therapeutics
ACRS
$732M
– –
-1,954,904
Closed -$35.2M
NVAX icon
6
Novavax
NVAX
$1.2B
– –
-5,000
Closed -$1.04M
EPZM
7
DELISTED
Epizyme, Inc
EPZM
– –
-998,278
Closed -$5.11M
XLRN
8
DELISTED
Acceleron Pharma
XLRN
– –
-108,630
Closed -$18.7M

Similar funds

PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
KCGDR
Kiron Capital Gestao de Recursos Sao Paulo, Brazil $36.9M AUM 49.85% 1-Year Est. Return
SEM
Spectrum Equity Management San Francisco, California $39.1M AUM 63.69% 1-Year Est. Return
ALFIA
Accel Leaders Fund II Associates Palo Alto, California $36.6M AUM 58.14% 1-Year Est. Return
MCMI
Matrix China Management III Grand Cayman, Cayman Islands $39.3M AUM
LCM
LH Capital Markets New York $39.4M AUM 14.61% 1-Year Est. Return
HLC
Hunt Lane Capital New York $39.6M AUM 58.74% 1-Year Est. Return
KXA
KPCB XV Associates Menlo Park, California $35.8M AUM 57.59% 1-Year Est. Return

Foresite Capital Management III's Q4 2021 Portfolio in Review

As of Q4 2021, Foresite Capital Management III held 8 positions worth $39.5M, down 45% from $72.1M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Foresite Capital Management III withdrew a net $30.7M in Q4 2021, closing 4 positions. Its most notable exit was Aclaris Therapeutics, an estimated $35.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Foresite Capital Management III opened a new position in Ascendis Pharma A/S worth $18M.

  • Foresite Capital Management III's largest Q4 2021 buy was Ascendis Pharma A/S: 133,691 shares worth $18M.
  • Foresite Capital Management III fully exited Aclaris Therapeutics in Q4 2021, selling an estimated $35.2M.
  • Foresite Capital Management III's ten largest holdings make up 100% of its $39.5M portfolio in Q4 2021.
  • Foresite Capital Management III opened 2 new positions and closed 4 in Q4 2021.
  • Foresite Capital Management III's portfolio value fell 45% quarter-over-quarter to $39.5M.

Based on Foresite Capital Management III's 13F filing for Q4 2021, filed 11 Feb 2022.